Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$444.39
-0.8%
$460.50
$425.00
$616.00
$159.63B1.612.06 million shs1.01 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$190.82
+0.6%
$177.49
$140.68
$192.10
$459.67B0.48.89 million shs4.10 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.64
-1.0%
$25.98
$23.15
$59.73
$10.80B2.0110.87 million shs5.24 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$8.56
-3.8%
$8.26
$5.01
$13.34
$1.39B2.746.47 million shs3.63 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
+1.62%+2.29%-4.66%-14.82%-6.80%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.42%+2.02%+6.42%+20.31%+18.86%
Moderna, Inc. stock logo
MRNA
Moderna
+2.12%+1.16%+12.44%-18.55%-52.18%
Novavax, Inc. stock logo
NVAX
Novavax
-3.47%-6.32%+15.14%+25.35%-31.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$444.39
-0.8%
$460.50
$425.00
$616.00
$159.63B1.612.06 million shs1.01 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$190.82
+0.6%
$177.49
$140.68
$192.10
$459.67B0.48.89 million shs4.10 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.64
-1.0%
$25.98
$23.15
$59.73
$10.80B2.0110.87 million shs5.24 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$8.56
-3.8%
$8.26
$5.01
$13.34
$1.39B2.746.47 million shs3.63 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
+1.62%+2.29%-4.66%-14.82%-6.80%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.42%+2.02%+6.42%+20.31%+18.86%
Moderna, Inc. stock logo
MRNA
Moderna
+2.12%+1.16%+12.44%-18.55%-52.18%
Novavax, Inc. stock logo
NVAX
Novavax
-3.47%-6.32%+15.14%+25.35%-31.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.59
Moderate Buy$589.4331.41% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.73
Moderate Buy$189.88-0.51% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.00
Hold$41.8151.65% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.00
Hold$14.2964.32% Upside

Current Analyst Ratings Breakdown

Latest JNJ, ISRG, MRNA, and NVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
10/8/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+)Buy (B-)
10/8/2025
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Novavax, Inc. stock logo
NVAX
Novavax
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
10/7/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$200.00 ➝ $213.00
10/7/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetIn-Line$535.00 ➝ $450.00
10/6/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$172.00 ➝ $193.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$198.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetEqual WeightOverweight$170.00 ➝ $212.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual WeightOverweight$170.00 ➝ $212.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$175.00 ➝ $198.00
(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$8.35B19.25$8.13 per share55.20$46.41 per share9.66
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$90.63B5.07$13.25 per share14.40$29.69 per share6.43
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.33N/AN/A$28.33 per share0.97
Novavax, Inc. stock logo
NVAX
Novavax
$1.08B1.31N/AN/A($3.89) per share-2.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.32B$7.1762.6858.794.6428.51%14.56%12.93%10/21/2025 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$9.3520.4017.242.4125.00%32.49%13.00%10/14/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.283.82108.680.1239.20%-142.33%28.65%11/11/2025 (Estimated)

Latest JNJ, ISRG, MRNA, and NVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$1.95N/AN/AN/A$893.29 millionN/A
10/21/2025Q3 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.00N/AN/AN/A$2.41 billionN/A
10/14/2025Q3 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.78N/AN/AN/A$23.73 billionN/A
8/6/2025Q2 2025
Novavax, Inc. stock logo
NVAX
Novavax
-$0.07$0.62+$0.69$0.62$149.19 million$239.24 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
7/22/2025Q2 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.93$2.19+$0.26$1.81$2.35 billion$2.44 billion
7/16/2025Q2 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.202.74%N/A55.61%64 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A

Latest JNJ, ISRG, MRNA, and NVAX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.35%8/26/20258/26/20259/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
5.17
4.18
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.50
1.01
0.76
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
Novavax, Inc. stock logo
NVAX
Novavax
5.93
2.36
2.34

Institutional Ownership

CompanyInstitutional Ownership
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.70%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
15,638358.48 million355.97 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,1002.41 billion2.40 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800390.58 million347.62 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990162.42 million160.80 millionOptionable

Recent News About These Companies

Novavax Announces Progress on Sanofi Agreement
Brokerages Set Novavax, Inc. (NASDAQ:NVAX) Price Target at $14.29

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$444.39 -3.70 (-0.83%)
As of 03:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$190.82 +1.13 (+0.59%)
As of 03:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna stock logo

Moderna NASDAQ:MRNA

$27.64 -0.29 (-1.02%)
As of 03:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$8.56 -0.34 (-3.78%)
As of 03:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.